AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
AbbVie has raised its revenue and EPS guidance, indicating strong financial performance. Skyrizi and Rinvoq are expected to exceed guidance, and there is optimism in the neuroscience and immunology portfolios. Despite challenges in the aesthetics market and Humira erosion, the company anticipates growth driven by pipeline advancements and strategic acquisitions. The Q&A highlighted strong competitive positioning and market share gains. While some uncertainties remain, the overall sentiment is positive, suggesting a stock price increase in the short term.
Key Financial Performance
Adjusted Earnings Per Share (EPS) $1.86, which is $0.10 above the guidance midpoint. The increase was attributed to strong financial performance and operational execution.
Total Net Revenues Nearly $15.8 billion, reflecting an 8.4% growth on an operational basis. This exceeded expectations by approximately $300 million, driven by strong sales growth in immunology and neuroscience.
Immunology Revenues Approximately $7.9 billion, up 11.2% on an operational basis. Growth was driven by Skyrizi and Rinvoq, with Skyrizi global sales at $4.7 billion (46% operational growth) and Rinvoq global revenues at nearly $2.2 billion (34.1% operational growth).
Neuroscience Revenues More than $2.8 billion, up 19.6% on an operational basis. Growth was driven by strong performance in the migraine portfolio and Vraylar sales.
Oncology Revenues Nearly $1.7 billion, relatively flat versus the prior year. Growth from Venclexta and newer products offset the decline in Imbruvica sales due to competitive dynamics.
Aesthetics Revenues Approximately $1.2 billion, down 4.2% on an operational basis. Decline attributed to challenging market conditions and low consumer sentiment, particularly in the U.S.
Humira Global Sales $993 million, down 55.7% on an operational basis. Decline due to biosimilar competition.
Adjusted Gross Margin 83.9% of sales, reflecting strong operational performance.
Adjusted R&D Expense 14.3% of sales, with a total of $9 billion anticipated for 2025. Increase supports pipeline opportunities in core areas like immunology, oncology, neuroscience, and aesthetics.
Adjusted SG&A Expense 21.6% of sales, reflecting investments in commercial capabilities and promotional activities.
Free Cash Flow Approximately $13 billion generated in the first 9 months of the year, including $2.2 billion of Skyrizi royalty payments.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Skyrizi and Rinvoq: Combined sales growth of more than 40%, with Skyrizi global sales at $4.7 billion (46% growth) and Rinvoq global revenues at $2.2 billion (34.1% growth). Expanded indications for Rinvoq in IBD and other conditions.
Pipeline Advancements: Approximately 90 programs across all stages of development, including new product approvals for tavapadon and PVEK, and pivotal data for lutikizumab, Temab-A, and etentamig.
Acquisitions: Acquisition of Gilgamesh's bretisilocin for psychiatry pipeline and Capstan Therapeutics for immunology pipeline.
Immunology Market: Skyrizi and Rinvoq achieved in-play share leadership in Crohn's disease and ulcerative colitis across multiple countries. Skyrizi holds 50% in-play patient share for biologics in the U.S.
Neuroscience Market: Qulipta became the #1 CGRP treatment for migraine prevention with a 7.5% prescription share. VYALEV's Parkinson's treatment uptake exceeded expectations.
Aesthetics Market: Global sales of $1.2 billion, down 4.2% due to challenging market conditions and low consumer sentiment.
Revenue Growth: Total net revenues of $15.8 billion, reflecting 8.4% operational growth. Neuroscience revenues grew by 19.6%.
R&D Investment: $9 billion adjusted R&D expense planned for 2025, supporting pipeline opportunities in immunology, oncology, neuroscience, and aesthetics.
Dividend Growth: 5.5% increase in quarterly cash dividend, marking a 330% growth since inception.
Long-term Growth Investments: Investing $10 billion in U.S. capital over the next 10 years, including new manufacturing sites and R&D capacity expansion.
Shift in Treatment Paradigm: Rinvoq's label update allows use prior to anti-TNFs in IBD, reflecting a shift towards newer, higher efficacy agents.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Biosimilar Competition: Humira sales have declined significantly (down 55.7%) due to biosimilar competition, and further erosion is expected as more plans select exclusionary contracts for existing patients.
Market Conditions in Aesthetics: Global sales in aesthetics are down 4.2% due to challenging market conditions, low consumer sentiment, and economic concerns, particularly in the U.S., impacting discretionary spending.
Competitive Dynamics in Oncology: Imbruvica sales continue to decline due to competitive pressures in the chronic lymphocytic leukemia (CLL) market.
Economic and Inflationary Pressures: Concerns about the economy and inflation are weighing on consumer discretionary spending, particularly affecting the aesthetics segment.
Regulatory and Approval Risks: Several pipeline programs, including tavapadon and PVEK, are awaiting regulatory approvals, which carry inherent risks of delays or non-approval.
Supply Chain and Manufacturing Investments: Significant investments in manufacturing and R&D facilities, such as the new API manufacturing site in North Chicago, could face execution risks or cost overruns.
Dependence on Key Products: The company’s growth heavily relies on Skyrizi and Rinvoq, which may face future competitive or market challenges.
Macroeconomic Uncertainty: Global economic uncertainties could impact overall business performance, particularly in consumer-driven segments like aesthetics.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2025 Adjusted Earnings Per Share Guidance: AbbVie raised its full-year adjusted earnings per share guidance to between $10.61 and $10.65.
Revenue Projections: Total net revenues for 2025 are expected to be approximately $16.9 billion, an increase of $400 million from prior guidance. Neuroscience global revenues are projected at $10.7 billion, reflecting continued strength across Vraylar, Botox Therapeutic, VYALEV, and the total oral CGRP portfolio. Aesthetics total sales are projected at $4.9 billion, reflecting market softness globally.
Skyrizi and Rinvoq Growth: Skyrizi global sales are projected to reach $17.3 billion, reflecting continued share gains in psoriasis and IBD. Rinvoq is expected to continue its strong growth trajectory, supported by expanded indications and label updates.
Pipeline Milestones: Several important milestones are expected over the next two years, including new product approvals for tavapadon and PVEK, expanded indications for Rinvoq, Epkinly, Qulipta, and Ubrelvy, and pivotal data for lutikizumab, Temab-A, and etentamig.
R&D Investment: AbbVie anticipates $9 billion of adjusted R&D expense in 2025, supporting numerous pipeline opportunities across core areas such as immunology, oncology, neuroscience, and aesthetics, as well as new growth areas like obesity.
Capital Allocation: AbbVie plans to invest at least $10 billion of capital in the U.S. over the next 10 years, including construction of a new API manufacturing site in North Chicago and expansion of biologics manufacturing and R&D capacity in Worcester.
Dividend Growth: AbbVie announced a 5.5% increase in its quarterly cash dividend, beginning with the dividend payable in February 2026.
Aesthetics Market Outlook: While the aesthetics market is currently facing challenging conditions due to low consumer sentiment and economic concerns, AbbVie remains optimistic about long-term growth potential, supported by new consumer campaigns and product innovations.
Neuroscience Expansion: AbbVie is actively expanding its field sales team to support higher anticipated demand for its emerging Parkinson's portfolio, including tavapadon and VYALEV.
Oncology Pipeline: AbbVie is advancing its oncology pipeline with promising programs like Temab-A, which has shown durable efficacy and manageable safety profiles in difficult-to-treat cancers. Phase III and Phase II studies for various indications are planned.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Growth: AbbVie announced a 5.5% increase in its quarterly cash dividend, starting with the dividend payable in February 2026. Since its inception, AbbVie has grown its quarterly dividend by more than 330%.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the potential implications for AbbVie's business of the new PBM model discussed by Cigna?
A:CEO Robert Michael and EVP Jeffrey Stewart emphasized that AbbVie is confident in adapting to any changes in the PBM model due to their differentiated medicines and strong execution track record. They highlighted AbbVie's ability to perform well in markets without PBMs and DTC advertising. They also noted that they are in regular discussions with Cigna and are studying the details of the new model.
Q:Can you comment on the IRA price negotiations for Vraylar and Linzess?
A:Robert Michael stated that the prices are not yet public but noted that the administration focused on achieving greater reductions this year. He assured that the outcomes for Vraylar and Linzess will not impact AbbVie's long-term guidance.
Q:What are the competitive dynamics and positioning in the IL-23 market, particularly with Skyrizi and TREMFYA?
A:Jeffrey Stewart highlighted Skyrizi's strong growth (46% year-over-year) and leadership position in IBD. He noted that while TREMFYA is gaining market share, the IL-23 class is expanding rapidly, with penetration in ulcerative colitis increasing from 5% to nearly 40% in a year. Skyrizi and Rinvoq together provide a strong competitive position for AbbVie.
Q:What is AbbVie's outlook for 2026 and the factors influencing it?
A:Robert Michael mentioned that AbbVie has raised its revenue forecast for 2025 by nearly $2 billion and expects strong growth in 2026 despite headwinds from Humira erosion and Imbruvica IRA pricing. He highlighted the overperformance of Skyrizi, Rinvoq, and the neuroscience portfolio as key drivers.
Q:Will AbbVie update its long-term guidance for Skyrizi and Rinvoq?
A:Robert Michael indicated that AbbVie is on track to exceed its 2027 guidance for Skyrizi and Rinvoq, as evidenced by the $1.7 billion increase in 2025 guidance. He emphasized the company's diversified growth platform and pipeline depth as key strengths.
Q:What are the latest market shares for BOTOX and Juvederm in the U.S.?
A:Jeffrey Stewart reported that BOTOX holds a market share in the low 60s, while Juvederm's HA filler market share is around 45%. He noted that the U.S. toxin market is flat, and the filler market is down double digits year-over-year.
Q:What are AbbVie's plans for the Gilgamesh acquisition and its potential in MDD treatment?
A:Roopal Thakkar explained that the acquired psychedelic has a short duration of action and potential for long-lasting effects after 1-2 doses. AbbVie plans to explore different doses and treatment paradigms in Phase II and III studies, with a focus on major depression and other mood disorders.
Q:What is the uptake and competitive positioning of VYALEV in the Parkinson's market?
A:Jeffrey Stewart and Roopal Thakkar highlighted VYALEV's strong uptake, capturing 80-85% of the in-play market. They emphasized its 24-hour coverage, low dyskinesia rates, and minimal need for supplemental oral therapies as key competitive advantages.
Q:What are the top pipeline candidate readouts to focus on in the next 6 months?
A:Roopal Thakkar mentioned key readouts in immunology (IBD platform, lutikizumab), oncology (Temab-A, etentamig), neuroscience (VRAYLAR-932, emraclidine), and obesity (Amylin asset). These include data on combination therapies, new indications, and novel mechanisms.
Q:What is the outlook for accelerating growth as Humira's absolute dollar declines diminish?
A:Scott Reents stated that while Humira's erosion will continue, its absolute dollar declines will diminish. AbbVie expects high single-digit revenue growth through the decade, driven by strong performance across its portfolio and operating margin expansion.
Q:What is the size of the opportunity for Rinvoq in nonsegmental vitiligo?
A:Jeffrey Stewart noted that Rinvoq's opportunity in nonsegmental vitiligo is part of a broader set of new indications, including alopecia areata, HS, and lupus, which collectively have a revenue potential of at least $2 billion at peak.
Q:What are AbbVie's next steps with its CAR-T and oral peptide platforms in immunology?
A:Roopal Thakkar outlined plans to optimize dosing and expand into rheumatology indications like RA and lupus for the CAR-T platform. For oral peptides, AbbVie is focusing on extending half-life and potency, with lead candidates targeting IL-23 and TL1A.
Q:How does AbbVie view the competition from oral IL-23 inhibitors?
A:Roopal Thakkar emphasized Skyrizi's strong efficacy and durability, noting that it offers quarterly dosing and head-to-toe benefits. AbbVie is confident in Skyrizi's competitive position against oral IL-23 inhibitors.
Q:What are AbbVie's thoughts on M&A and business development priorities?
A:Robert Michael stated that AbbVie focuses on assets that drive growth into the next decade, particularly in immunology, neuroscience, oncology, aesthetics, and obesity. Recent acquisitions like Capstan and Gilgamesh align with this strategy.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the IRA price negotiations for Vraylar and Linzess, stating only that the prices are not yet public. Additionally, they did not quantify the expansion opportunity associated with the changes to the Rinvoq label, describing it only as a net incremental positive.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ADC potential
AbbVie
Epkinly
II study
MET tumor
Phase II
RA patient
RD
Rinvoq TNF
Rinvoq label
Rinvoq play
Rinvoq superiority
Roopal
SELECT SWITCH
SWITCH trial
TNF inhibitor
TNFs patient
Temab
TrenibotE
VYALEV
allocation priority
anxiety
basis portfolio
benefit Rinvoq
bevacizumab
bretisilocin
cancer rate
capital allocation
cash flow
disease control
dividend
dose response
fluctuation
improvement
inception
line result
patient line
result Phase
study Rinvoq
tremor
ABBV Transcript
AbbVie Inc. (ABBV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-9
AbbVie Inc. (ABBV) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
AbbVie Inc. (ABBV) Q1 2026 Earnings Call Transcript
Positive4-29
The earnings call summary shows strong financial performance with a 5% revenue increase and a 7% net earnings growth. The EPS rose by 6%, and the gross margin improved by 2%. These positive metrics, along with a 10% increase in operating cash flow, indicate robust financial health. Despite the lack of operational updates or strategic initiatives discussed, the financial results suggest a positive sentiment. However, the absence of forward-looking guidance and strategic initiatives discussion tempers the outlook slightly, leading to an overall positive rating.
Volkswagen AG (VWA:CA) Q4 2025 Earnings Call Transcript
Positive3-10
The earnings call highlights strong financial performance, with a significant increase in financial services operating results and positive guidance for future margins. Despite challenges like U.S. tariffs and competition, the company is focused on cost reductions and strategic growth in key regions. The Q&A section reveals management's proactive approach to regulatory discussions and investment plans, particularly in electrification and efficiency. While some uncertainties remain, the overall sentiment is optimistic, supported by strategic initiatives and a commitment to shareholder returns.
ABBV Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
